Results from the phase 2 VIM trial support the use of vinorelbine in patients with malignant pleural mesothelioma whose disease has progressed following platinum-based therapy.

After a median follow-up of 41.0 months, the risk for death was reduced by a significant 22% among the 302 participants who were randomly assigned to receive atezolizumab 1200 mg on day 1 of each 21-day cycle compared with their 151 counterparts who instead received vinorelbine or gemcitabine in 3-weekly or 4-weekly cycles.

This was nearly double the median PFS achieved by their counterparts who received investigator’s choice of docetaxel plus capecitabine, paclitaxel plus gemcitabine, or capecitabine plus vinorelbine, at 12.3 months, and equated to a significant 46% reduction in the risk for progression or death with ribociclib plus ET.

ESMO 2022 video The current presentation focused on the second interim analysis for OS, which was conducted at a median follow-up of 12.5 months and demonstrated that OS was significantly prolonged for the 272 participants who were randomly allocated to receive sacituzumab govitecan 10 mg/kg on days 1 and 8 of every 21-day cycle compared with the 271 patients who instead received physician’s choice of capecitabine, vinorelbine, gemcitabine, or eribulin.

This was significantly longer than the median duration of 4.0 months for their 271 counterparts who instead received physician’s choice of capecitabine, vinorelbine, gemcitabine, or eribulin.

Median OS was 7.8 months for the 92 patients with pretreated, nonprogressive brain metastases who were randomly assigned to receive etirinotecan pegol 145 mg/m 2 every 21 days and a comparable 7.5 months for their 86 counterparts instead given physicians’ choice of single-agent eribulin, ixabepilone, vinorelbine, gemcitabine, paclitaxel, docetaxel, or nab-paclitaxel.

Adjuvant gefitinib does not significantly improve overall survival relative to vinorelbine plus cisplatin in patients with completely resected stage II–IIIA, EGFR -mutant non-small-cell lung cancer, final data from the ADJUVANT-CTONG1104 trial show.

The phase 3 trial investigators randomly assigned 622 patients from 31 countries who had received one or two prior treatments for metastatic TNBC to receive pembrolizumab 200 mg every 3 weeks for 35 cycles or an investigator’s choice of single-agent chemotherapy, either capecitabine, eribulin, gemcitabine, or vinorelbine.

The 536 trial participants – all of whom had received at least two prior HER2-directed therapies and 1–3 nonhormonal treatments for metastatic disease – were randomly assigned to receive either margetuximab 15 mg/kg or trastuzumab 6 mg/kg (loading dose 8 mg/kg) once every 21 days alongside physician’s choice of capecitabine, eribulin, gemcitabine, or vinorelbine.

Bardia video He said that the ASCENT study was initiated to confirm these results and recruited 529 metastatic TNBC patients (primarily women) who had received at least two lines of chemotherapy, randomly assigning them to receive either intravenous SG 10 mg/kg on days 1 and 8 of every 3-week cycle or physician’s choice of capecitabine, eribulin, vinorelbine, or gemcitabine.

This did not differ significantly from the median PFS of 3.4 months observed among the 71 patients given single-agent chemotherapy, either gemcitabine or vinorelbine.

In this phase III trial, patients with malignant pleural mesothelioma that has progressed despite platinum-based treatment receive either immunotherapy with pembrolizumab or standard chemotherapy (gemcitabine or vinorelbine).

They report a significant progression-free survival (PFS) gain for the 79 patients who were randomly assigned to receive the triple regimen compared with the 79 patients who instead were given trastuzumab plus a physician’s choice of single-agent chemotherapy, such as vinorelbine or capecitabine, at 8.3 versus 5.7 months and a hazard ratio for progression or death of 0.67.

Previously the primary endpoint of progression-free survival in the phase 3 study  found a significant benefit with talazoparib 1 mg/day versus capecitabine, eribulin, gemcitabine, or vinorelbine.

The participants of one cohort, all of whom had tumor cell PD-L1 levels of at least 25%, were randomly assigned to receive durvalumab 10 mg/kg every 2 weeks for up to a year or investigator’s choice of one of three standard of care (SOC) therapies, namely, erlotinib, gemcitabine, or vinorelbine.

The 5-year disease-free survival (DFS) rate was 77.6% for the 185 patients randomly assigned to receive a 24-week maintenance regimen of vinorelbine 25 mg/m 2 on days 1, 8, and 15 of a 28-day cycle, alongside daily cyclophosphamide 25 mg/m 2 per day.

Median PFS was 8.6 months for the 287 patients randomly assigned to receive open-label talazoparib 1 mg/day compared with a median PFS of 5.6 months for the 144 patients who instead received physician’s choice of single-agent therapy with capecitabine, eribulin, gemcitabine, or vinorelbine.

Yi-Long Wu (Guangdong Lung Cancer Institute, Guangzhou, China) and colleagues randomly assigned 222 adults at one of 27 Chinese centers to receive either gefitinib 250 mg/day for 24 months or intravenous vinorelbine and cisplatin every 3 weeks for four cycles.

Overall, 25% of patients received vinorelbine, 23% received docetaxel, 19% received gemcitabine, and 33% received pemetrexed, report Heather Wakelee (Stanford University, California, USA) and colleagues.